Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* This study includes two semi-consecutive parts:

* Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.
* Part II Prospective, controlled, blinded part to determine the performance of the CellDetect® device in monitoring bladder cancer recurrence in patients with a history of TCC, using urine cytology samples
* The following subjects will be enrolled:

Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors

NCT02966691

Bladder Cancer

COMPLETED NA

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

NCT05046665

Urothelial Carcinoma

COMPLETED PHASE1

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

NCT02735512

No Evidence of Disease Stage II Bladder Cancer Stage III Bladder Cancer +2 more

TERMINATED

Personalized Urine Biomarker for Patients With Bladder Cancer

NCT05467267

Bladder Neoplasm

UNKNOWN

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

NCT02700464

Bladder Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study aim:

1. To calibrate the CellDetect® device for detecting TCC in urine cytology samples.
2. Determine the performance of the CellDetect® device in identifying TCC recurrence in patients with a history of TCC using urine cytology samples.

The study includes two parts:

Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.

Part II Prospective, controlled, blinded part to determine the performance of the CellDetect® device in monitoring bladder cancer recurrence in in patients with a history of TCC, using urine cytology samples

\* The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

Part I - up to 200 urine eligible samples Part II - up to 300 urine eligible samples

Endpoints:

1. To calibrate the CellDetect® device for identifying TCC in urine cytology samples.
2. To determine the performance of the CellDetect® device in identifying recurrence of TCC in urine samples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer Transitional Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cystoscopic surveillance, TURT or Cystectomy

The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group A (Monitoring group):

1. Subjects diagnosed with bladder cancer undergoing routine cystoscopic surveillance, who had normal cystoscopies for at least 12 months..
2. Ability to provide informed consent
3. Age \> 18 years

Group B (Positive group):

1. Subject undergoing TURT or cystectomy due to any of the following reasons:

* Subjects with suspected or known TCC (hematuria subjects)
* Subjects with previously diagnosed TCC undergoing routine cystoscopic surveillance.
2. Ability to provide informed consent
3. Age \> 18 years

Subjects meeting the following criteria (all of them) will be included in the study:

1. Subject with a documented history of TCC and who are undergoing routine cystoscopic surveillance, TURBT or cystectomy
2. At least 4 weeks have passed since any treatment for TCC (including cystoscopy and/or TURBT procedures)
3. Ability to provide informed consent
4. Age ≥ 18 years old

Exclusion Criteria

1. Participation in another clinical trial within last 30 days.
2. Known pregnancy on day of screening.

Part B:

1. Subject with catheters, neobladder or kidney stones.
2. Subject unable to provide a spontaneous urine sample.
3. Subject currently under any cancer drug treatment.
4. No biopsy results available for subjects with positive findings on cystoscopy test, TURBT or cystectomy. \[Note: such subjects will be excluded after recruitment and urine collection, as result of the delay in receiving biopsy results\].
5. If more than 3 months have passed between urine sample collection and TURBT or cystectomy procedures, and no second sample was taken before undergoing TURBT, subject will be excluded from the study.
6. Subject undergoing TURBT or cystectomy whose biopsy results demonstrated abnormal findings other than TCC.
7. Subject participated in another clinical study within the last 30 days.
8. Known pregnancy on day of screening.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No